BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 21575500)

  • 1. [Analysis of risk factors for relapse of 82 patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation].
    Yu ZP; Ding JH; Chen BA; Wu F; Gao C; Sun YY; Chen J; Zhao G; Wang J; Li YF; Ding BH; Qian J
    Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):283-6. PubMed ID: 21575500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.
    Chen XH; Zhang C; Zhang X; Gao L; Gao L; Kong PY; Peng XG; Qi DG; Sun AH; Zeng DF; Liu H; Gong Y; Wang QY
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):266-73. PubMed ID: 19167687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation.
    Ikegame K; Yoshihara S; Taniguchi Y; Kaida K; Inoue T; Okada M; Taniguchi K; Hasei H; Tamaki H; Fujioka T; Kato R; Soma T; Ogawa H
    Exp Hematol; 2011 Aug; 39(8):880-90. PubMed ID: 21689724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic transplantation of G-CSF mobilized peripheral blood stem cells from unrelated donors: a retrospective analysis.
    Bornhäuser M; Theuser C; Soucek S; Hölig K; Klingebiel T; Blau W; Fauser A; Runde V; Schwinger W; Rutt C; Ehninger G
    Haematologica; 2000 Aug; 85(8):839-47. PubMed ID: 10942931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment and outcome of chronic graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation in pediatric patients.
    Diaz MA; Vicent MG; Gonzalez ME; Verdeguer A; de la Rubia J; Bargay J; de Arriba F; Diez JL; Caballero D; Madero L; Brunet S;
    Bone Marrow Transplant; 2004 Sep; 34(5):433-8. PubMed ID: 15273704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical study of allogeneic hematopoietic stem cell transplantation for relapsed/refractory acute lymphocytic leukemia].
    Ma X; Wu DP; Sun AN; Fu ZZ; Tang XW; Wu XJ; Liu YJ; Qiu HY; Miao M; Han Y; Jin ZM; Zhao Y; Xue SL; Wang Y; Chen SN; He GS; Zhou HX; Chang HR
    Zhonghua Xue Ye Xue Za Zhi; 2009 Feb; 30(2):73-6. PubMed ID: 19563014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
    Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A comparison of clinical outcomes between unrelated donor and HLA-haploidentical donor hematopoietic stem cell transplantation].
    Chen F; Wu DP; Sun AN; Ma X; Tang XW; Qiu HY; Miao M; Fu ZZ; Jin ZM; Wang Y; Wu XJ; Chen SN; He GS; Wang XL; Xue SL; Zhao Y; Chang WR
    Zhonghua Xue Ye Xue Za Zhi; 2008 Feb; 29(2):83-6. PubMed ID: 18681306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Allogeneic peripheral blood stem cell transplantation in the treatment of hematologic malignancies].
    Wang F; Huang X; Ren H; Zhang Y; Xu L; Chen Y; Liu K; Guo N; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 2002 Aug; 23(8):403-6. PubMed ID: 12411042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epileptic seizures in patients following allogeneic hematopoietic stem cell transplantation: a retrospective analysis of incidence, risk factors, and survival rates.
    Zhang XH; Xu LP; Liu DH; Chen H; Han W; Chen YH; Wang FR; Wang JZ; Wang Y; Zhao T; Chen Y; Fu HX; Liu KY; Huang XJ
    Clin Transplant; 2013; 27(1):80-9. PubMed ID: 22938074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation].
    Chen Y; Xu Y; Zhu Y; Fu G; Liu Y; Peng J; Fu B; He Q; Wu D; Li X; Zhao X; Chen F
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Sep; 36(9):859-64. PubMed ID: 21946205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel approach to human leukocyte antigen-mismatched transplantation in patients with malignant hematological disease.
    Huang XJ; Han W; Xu LP; Chen YH; Liu DH; Lu J; Chen H; Zhang YC; Jiang Q; Liu KY; Lu DP
    Chin Med J (Engl); 2004 Dec; 117(12):1778-85. PubMed ID: 15603704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, risks, and outcome of idiopathic pneumonia syndrome early after allogeneic hematopoietic stem cell transplantation.
    Zhu KE; Hu JY; Zhang T; Chen J; Zhong J; Lu YH
    Eur J Haematol; 2008 Dec; 81(6):461-6. PubMed ID: 18774951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.